NASDAQ:AXSM Axsome Therapeutics - AXSM Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Axsome Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $60.55 -1.89 (-3.03%) (As of 03/30/2023 12:00 AM ET) Add Compare Share Share Today's Range$58.69▼$63.0050-Day Range$58.39▼$75.0052-Week Range$20.63▼$82.00Volume1.11 million shsAverage Volume964,320 shsMarket Capitalization$2.64 billionP/E RatioN/ADividend YieldN/APrice Target$103.93 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Axsome Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.69 Rating ScoreUpside/Downside71.6% Upside$103.93 Price TargetShort InterestBearish24.83% of Float Sold ShortDividend StrengthN/ASustainability-1.03Upright™ Environmental ScoreNews Sentiment0.13Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($4.61) to ($1.27) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.40 out of 5 starsMedical Sector218th out of 1,009 stocksPharmaceutical Preparations Industry90th out of 494 stocks 4.3 Analyst's Opinion Consensus RatingAxsome Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.69, and is based on 10 buy ratings, 2 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $103.93, Axsome Therapeutics has a forecasted upside of 71.6% from its current price of $60.55.Amount of Analyst CoverageAxsome Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted24.83% of the float of Axsome Therapeutics has been sold short.Short Interest Ratio / Days to CoverAxsome Therapeutics has a short interest ratio ("days to cover") of 8.9.Change versus previous monthShort interest in Axsome Therapeutics has recently increased by 1.55%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAxsome Therapeutics does not currently pay a dividend.Dividend GrowthAxsome Therapeutics does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAxsome Therapeutics has received a 69.39% net impact score from Upright. The largest positive contribution comes from its "Mental diseases" impact, which is driven by its "Clinical research services for mental health" product. See details.Environmental SustainabilityThe Environmental Impact score for Axsome Therapeutics is -1.03. Previous Next 1.7 News and Social Media Coverage News SentimentAxsome Therapeutics has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Axsome Therapeutics this week, compared to 5 articles on an average week.Search InterestOnly 43 people have searched for AXSM on MarketBeat in the last 30 days. This is a decrease of -52% compared to the previous 30 days.MarketBeat FollowsOnly 9 people have added Axsome Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -18% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Axsome Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders26.00% of the stock of Axsome Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions59.71% of the stock of Axsome Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Axsome Therapeutics are expected to grow in the coming year, from ($4.61) to ($1.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Axsome Therapeutics is -13.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Axsome Therapeutics is -13.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAxsome Therapeutics has a P/B Ratio of 24.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Axsome Therapeutics (NASDAQ:AXSM) StockAxsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview contain AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.Read More Receive AXSM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Axsome Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AXSM Stock News HeadlinesMarch 30, 2023 | americanbankingnews.comAxsome Therapeutics (NASDAQ:AXSM) Trading Down 4.3%March 29, 2023 | nasdaq.comAxsome (AXSM) Down 9.8% Since Last Earnings Report: Can It Rebound?March 30, 2023 | Weiss Ratings (Ad)Bank Accounts: Frozen!In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!March 27, 2023 | markets.businessinsider.comMorgan Stanley Reaffirms Their Hold Rating on Axsome Therapeutics (AXSM)March 24, 2023 | markets.businessinsider.comMizuho Securities Remains a Buy on Axsome Therapeutics (AXSM)March 23, 2023 | americanbankingnews.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) Forecasted to Post Q4 2024 Earnings of $3.71 Per ShareMarch 22, 2023 | americanbankingnews.comHC Wainwright Brokers Cut Earnings Estimates for Axsome Therapeutics, Inc. (NASDAQ:AXSM)March 22, 2023 | americanbankingnews.comAxsome Therapeutics (NASDAQ:AXSM) Price Target Cut to $200.00 by Analysts at HC WainwrightMarch 30, 2023 | Weiss Ratings (Ad)Bank Accounts: Frozen!In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!March 20, 2023 | markets.businessinsider.comSVB Securities Sticks to Their Buy Rating for Axsome Therapeutics (AXSM)March 20, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Axsome Therapeutics (AXSM)March 17, 2023 | markets.businessinsider.comAxsome Therapeutics (AXSM) Receives a Buy from Mizuho SecuritiesMarch 11, 2023 | finance.yahoo.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) Q4 2022 Earnings Call TranscriptMarch 7, 2023 | 247wallst.comThese Are the Top 10 Holdings of David KimMarch 2, 2023 | msn.comAxsome Therapeutics Earnings Perspective: Return On Capital EmployedMarch 1, 2023 | markets.businessinsider.comAnalyst Expectations for Axsome Therapeutics's FutureMarch 1, 2023 | seekingalpha.comAxsome Therapeutics, Inc. (AXSM) Q4 2022 Earnings Call TranscriptMarch 1, 2023 | finance.yahoo.comAxsome Therapeutics to Present at Cowen’s 43rd Annual Health Care ConferenceFebruary 28, 2023 | finance.yahoo.comQ4 2022 Axsome Therapeutics Inc Earnings CallFebruary 27, 2023 | msn.comWhy Axsome Therapeutics (AXSM) Shares Are Trading HigherFebruary 27, 2023 | msn.comAxsome Therapeutics (AXSM) Reports Q4 Loss, Tops Revenue EstimatesFebruary 27, 2023 | finance.yahoo.comAxsome Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateFebruary 24, 2023 | msn.comAxsome Therapeutics's Earnings: A PreviewFebruary 23, 2023 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: United Therapeutics (UTHR) and Axsome Therapeutics (AXSM)February 22, 2023 | seekingalpha.comAxsome: Teva's ANDA Is No Surprise And No Big DealFebruary 22, 2023 | marketwatch.comAxsome Inks Overseas Sunosi License Deal With Pharmanovia >AXSMFebruary 22, 2023 | finance.yahoo.comAxsome Therapeutics Enters into License Agreement with Pharmanovia to Expand Commercialization and Further Develop Sunosi® (solriamfetol) in EuropeSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive AXSM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Axsome Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AXSM Company Calendar Last Earnings2/27/2023Today3/30/2023Next Earnings (Estimated)5/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AXSM CUSIPN/A CIK1579428 Webaxsome.com Phone(212) 332-3241Fax212-320-0245Employees108Year FoundedN/APrice Target and Rating Average Stock Price Forecast$103.93 High Stock Price Forecast$200.00 Low Stock Price Forecast$52.00 Forecasted Upside/Downside+71.6%Consensus RatingModerate Buy Rating Score (0-4)2.69 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($4.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-187,130,000.00 Net MarginsN/A Pretax Margin-373.99% Return on Equity-242.19% Return on Assets-76.51% Debt Debt-to-Equity Ratio0.86 Current Ratio2.54 Quick Ratio2.50 Sales & Book Value Annual Sales$50.04 million Price / Sales52.66 Cash FlowN/A Price / Cash FlowN/A Book Value$2.52 per share Price / Book24.03Miscellaneous Outstanding Shares43,520,000Free Float32,202,000Market Cap$2.64 billion OptionableOptionable Beta1.95 Key ExecutivesHerriott TabuteauChairman & Chief Executive OfficerMark L. JacobsonChief Operating OfficerNick PizzieChief Financial OfficerJoseph Debrah-AffulControllerLori EnglebertExecutive VP-Commercial & Business DevelopmentKey CompetitorsBlueprint MedicinesNASDAQ:BPMCUltragenyx PharmaceuticalNASDAQ:RAREArrowhead PharmaceuticalsNASDAQ:ARWRBausch Health CompaniesNYSE:BHCRevance TherapeuticsNASDAQ:RVNCView All CompetitorsInstitutional OwnershipMetLife Investment Management LLCBought 558 shares on 3/23/2023Ownership: 0.039%B. Riley Wealth Advisors Inc.Bought 3,361 shares on 3/15/2023Ownership: 0.008%Voya Investment Management LLCBought 863 shares on 2/28/2023Ownership: 0.038%Parallax Volatility Advisers L.P.Sold 46,000 shares on 2/27/2023Ownership: 0.000%B. Riley Wealth Advisors Inc.Bought 7,361 shares on 2/21/2023Ownership: 0.017%View All Institutional Transactions AXSM Stock - Frequently Asked Questions Should I buy or sell Axsome Therapeutics stock right now? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axsome Therapeutics in the last year. There are currently 1 sell rating, 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AXSM shares. View AXSM analyst ratings or view top-rated stocks. What is Axsome Therapeutics' stock price forecast for 2023? 13 Wall Street analysts have issued 12-month target prices for Axsome Therapeutics' shares. Their AXSM share price forecasts range from $52.00 to $200.00. On average, they expect the company's share price to reach $103.93 in the next year. This suggests a possible upside of 66.4% from the stock's current price. View analysts price targets for AXSM or view top-rated stocks among Wall Street analysts. How have AXSM shares performed in 2023? Axsome Therapeutics' stock was trading at $77.13 at the start of the year. Since then, AXSM shares have decreased by 19.0% and is now trading at $62.44. View the best growth stocks for 2023 here. When is Axsome Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 1st 2023. View our AXSM earnings forecast. How were Axsome Therapeutics' earnings last quarter? Axsome Therapeutics, Inc. (NASDAQ:AXSM) issued its earnings results on Monday, February, 27th. The company reported ($1.28) EPS for the quarter, missing the consensus estimate of ($1.18) by $0.10. The firm had revenue of $24.37 million for the quarter, compared to analyst estimates of $21.51 million. What ETFs hold Axsome Therapeutics' stock? ETFs with the largest weight of Axsome Therapeutics (NASDAQ:AXSM) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), Invesco DWA Healthcare Momentum ETF (PTH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Products ETF (BBP), iShares U.S. Pharmaceuticals ETF (IHE), Principal Healthcare Innovators ETF (BTEC) and Invesco DWA SmallCap Momentum ETF (DWAS). What other stocks do shareholders of Axsome Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Axsome Therapeutics investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Dicerna Pharmaceuticals (DRNA), Amarin (AMRN), Sarepta Therapeutics (SRPT), Micron Technology (MU), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA) and Bristol-Myers Squibb (BMY). When did Axsome Therapeutics IPO? (AXSM) raised $52 million in an initial public offering (IPO) on Thursday, November 19th 2015. The company issued 4,300,000 shares at $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. acted as the underwriters for the IPO and Brean Capital was co-manager. What is Axsome Therapeutics' stock symbol? Axsome Therapeutics trades on the NASDAQ under the ticker symbol "AXSM." Who are Axsome Therapeutics' major shareholders? Axsome Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Fairmount Funds Management LLC (4.63%), Alethea Capital Management LLC (1.81%), VR Adviser LLC (1.54%), Avidity Partners Management LP (1.54%), Point72 Asset Management L.P. (1.50%) and Geode Capital Management LLC (1.44%). Insiders that own company stock include Mark Coleman, Mark E Saad, Nick Pizzie and Roger Jeffs. View institutional ownership trends. How do I buy shares of Axsome Therapeutics? Shares of AXSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Axsome Therapeutics' stock price today? One share of AXSM stock can currently be purchased for approximately $62.44. How much money does Axsome Therapeutics make? Axsome Therapeutics (NASDAQ:AXSM) has a market capitalization of $2.72 billion and generates $50.04 million in revenue each year. The company earns $-187,130,000.00 in net income (profit) each year or ($4.57) on an earnings per share basis. How many employees does Axsome Therapeutics have? The company employs 108 workers across the globe. How can I contact Axsome Therapeutics? Axsome Therapeutics' mailing address is 200 BROADWAY 3RD FLOOR, NEW YORK NY, 10038. The official website for the company is axsome.com. The company can be reached via phone at (212) 332-3241 or via fax at 212-320-0245. This page (NASDAQ:AXSM) was last updated on 3/30/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.